

JC06 Rec'd PCT/PTO 11 AUG 2005


pct #3

Date: August 10, 2005

I hereby certify that, on the date indicated above, I deposited this paper with identified attachments and/or fee with the U.S. Postal Service and that it was addressed for delivery to the Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 by "First Class Mail" service.

Kim Blum
Name (Print)

Kim Blum
Signature



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Inventor Application of:	Akiyama et al.)	Examiner:	Unassigned
)		
Application No.:	10/537,001)	Group Art Unit:	Unassigned
)		
Filed:	May 20, 2005)	Confirmation No.:	Unassigned
)		
Docket No.:	3190-078)	Customer No.:	33432

For: COLON CANCER METASTASIS INHIBITOR

INFORMATION DISCLOSURE STATEMENT
PURSUANT TO 37 CFR 1.97(b)

Mail Stop Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

August 10, 2005

Sir:

The attention of the Patent and Trademark Office is hereby directed to the documents listed on the attached Form PTO/SB/08. Pursuant to the current United States Patent and Trademark Office rules, no copies of U.S. Patents/Patent Application Publications are provided.

This Information Disclosure Statement is being submitted before expiration of the three-month period following filing of the above-captioned application.

The above information is presented so that the Patent and Trademark Office can, in the first instance, determine any materiality thereof to the claimed invention. See 37 CFR 1.104(a) and 1.106(b) concerning the PTO duty to consider and use any such information. It is respectfully requested that the information be expressly considered during the prosecution of this application,


and that the documents cited in the attached Form PTO/SB/08 be made of record therein and appear on the first page of any patent to issue therefrom.

This submission does not represent that a search has been made or that no better art exists and does not constitute an admission that each or all of the listed documents are material or constitute "prior art." If the Examiner applies any of the documents as prior art against any claim in this application and applicant determines that the cited documents do not constitute "prior art" under United States law, applicant reserves the right to present to the office the relevant facts and law regarding the appropriate status of such documents.

Applicant further reserves the right to take appropriate action to establish the patentability of the disclosed invention over the listed documents, should one or more of the documents be applied against the claims of the present application.

It is believed that no fee is required to make this a complete and timely filing. However, if it is determined that a petition or fee is required, the Commissioner is hereby authorized to charge any fee associated with this statement to our Deposit Account No. 50-0925.

Respectfully submitted,



Luke A. Kilyk
Reg. No. 33,251

Atty. Docket No.: 3190-078
KILYK & BOWERSOX, P.L.L.C.
53 A East Lee Street
Warrenton, VA 20186
Tel.: (540) 428-1701
Fax: (540) 428-1720
Enclosures: PTO-SB-08, w/22 Documents

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**
(use as many sheets as necessary)

Sheet	1	of	2
-------	---	----	---

Complete if Known

Application Number	10/537,001
Filing Date	May 20, 2005
First Named Inventor	AKIYAMA et al.
Art Unit	Unassigned
Examiner Name	Unassigned
Attorney Docket Number	3190-078

U.S. PATENT DOCUMENTS

[illegible]

FOREIGN PATENT DOCUMENTS

[illegible]

Examiner
Signature

Date
Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹Applicant's unique citation designation number (optional). ²See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached. Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 2231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P. O. Box 1450, Alexandria, VA 22313-1450.

Substitute for form 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)				Complete if Known	
				Application Number	10/537,001
				Filing Date	May 20, 2005
				First Named Inventor	AKIYAMA et al.
				Art Unit	Unassigned
				Examiner Name	Unassigned
				Attorney Docket Number	3190-078
Sheet	2	of	2		

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date page(s), volume-issue number(s), publisher, city, and/or country where published.	T ²
		KAWASAKI et al., "Mutated APC and Asef are Involved in the Migration of Colorectal Tumor Cells," NATURE CELL BIOLOGY, Vol. 5, March 2003 (pgs. 211-215).	
		JIMBO et al., "A New Stage of a Study of APC Protein," MOLECULAR MEDICINE, Vol. 39, No. 11, 2002 (pgs. 1274 - 1279) (with partial English translation).	
		AKIYAMA, "The Tumor Suppressor Gene Product APC and Asef," JOURNAL OF CLINICAL AND EXPERIMENTAL MEDICINE, Vol. 205, No. 13, 2003 (pg. 1001) (with partial English translation).	
		KAWASAKI et al., "A Mutated APC/Asef Complex is Involved in Motility of Colorectal Cancer Cells," SUPPLEMENT OF JAPANESE JOURNAL OF CANCER RESEARCH, No. 3048, Vol. 61, 2002 (pg. 111) (with partial English translation).	
		KAWASAKI et al., "Asef, a Link Between the Tumor Suppressor APC and G-Protein Signaling," SCIENCE, Vol. 289, August 18, 2000 (pgs. 1194-1197).	
		KAWASAKI et al., "A Novel Function of the Tumor Suppressor Gene Product APC," PROTEIN, NUCLEIC ACID AND ENZYME, Vol. 46, No. 3, 2001 (pgs. 228-232) (with partial English translation).	
		SENDA, "APC Tumor Suppressor Gene -- Diversity of its Expression and Functions," JPN. J. CLIN. ELECTRON MICROSC., Vol. 33, No. 2, 2001 (pgs. 65-74) (with partial English translation).	
		PADDISON et al., "Short Hairpin RNAs (shRNAs) Induce Sequence-Specific Silencing in Mammalian Cells," GENES & DEVELOPMENT, Vol. 16, No. 8, 2002 (pgs. 948-958).	
		JENUWEIN, "An RNA-Guided Pathway for the Epigenome," SCIENCE, Vol. 297, September 27, 2002 (pgs. 2215-2218).	
		KINZLER et al., "Lessons from Hereditary Colorectal Cancer," CELL, Vol. 87, October 18, 1996 (pgs. 159-170).	
		FEARNHEAD et al., "The ABC of APC," HUMAN MOLECULAR GENETICS, Vol. 10, No. 7, 2001 (pgs. 721-733).	
		BIENZ et al., "Linking Colorectal Cancer to Wnt Signaling," CELL, Vol. 103, October 13, 2000 (pgs. 311-320).	
		PEIFER et al., "Wnt Signaling in Oncogenesis and Embryogenesis -- A Look Outside the Nucleus," SCIENCE, Vol. 287, March 3, 2000 (pgs. 1606-1609).	
		AKIYAMA, "Wnt/ β -Catenin Signaling," CYTOKINE & GROWTH FACTOR REVIEWS, Vol. 11, 2000 (pgs. 273-282).	
		MIYOSHI et al., "Somatic Mutations of the APC Gene in Colorectal Tumors: Mutation Cluster Region in the APC Gene," HUMAN MOLECULAR GENETICS, Vol. 1, No. 4, 1992 (pgs. 229-233).	
		NAGASE et al., "Mutations of the APC (Adenomatous Polyposis Coli) Gene," HUMAN MUTATION, Vol. 2, 1993 (pgs. 425-434).	
		MOLENAAR et al., "XTcf-3 Transcription Factor Mediates β -Catenin-Induced Axis Formation in Xenopus Embryos," CELL, Vol. 86, August 9, 1996 (pgs. 391-399).	
		BEHRENS et al., "Functional Interaction of β -Catenin With the Transcription Factor LEF-1," NATURE, Vol. 382, August 15, 1996 (pgs. 638-642).	
		WONG et al., "Forced Expression of the Tumor Suppressor Adenomatosis Polyposis Coli Protein Induces Disordered Cell Migration in the Intestinal Epithelium," PROC. NATL. ACAD. SCI, USA, Vol. 93, September 1996 (pgs. 9588-9593).	
		OSHIMA et al., "Morphological and Molecular Processes of Polyp Formation in Apc ^{Δ715} Knockout Mice," CANCER RESEARCH, Vol. 57, May 1, 1997 (pgs. 1644-1649).	
		International Search Report for PCT/JP03/10449 dated December 2, 2003.	
Examiner Signature		Date Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹Applicant's unique citation designation number (optional). ²See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. "Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). "For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. "Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. "Applicant is to place a check mark here if English language Translation is attached. Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P. O. Box 1450, Alexandria, VA 22313-1450.